

21. Mishina, M., Takai, T., Imoto, K., Noda, M., Takahashi, T., Numa, S., Methfessel, C. and Sakmann, B. 1986, *Nature*, 321, 406.
22. Lee, W.Y., Free, C.R. and Sine, S.M. 2009, *J. Neurosci.*, 29, 3189.
23. Mukhtasimova, N., Lee, W.Y., Wang, H.L. and Sine, S.M. 2009, *Nature*,
24. Ohno, K., Anlar, B. and Engel, A.G. 1999, *Neuromuscul. Disord.*, 9, 131.
25. Ohno, K., Quiram, P.A., Milone, M., Wang, H.-L., Harper, M.C., Pruitt, J.N., 2nd, Brengman, J.M., Pao, L., Fischbeck, K.H., Crawford, T.O., Sine, S.M. and Engel, A.G. 1997, *Hum. Mol. Genet.*, 6, 753.
26. Engel, A.G., Ohno, K., Bouzat, C., Sine, S.M. and Griggs, R.C. 1996, *Ann. Neurol.*, 40, 810.
27. Michalk, A., Stricker, S., Becker, J., Rupps, R., Pantzar, T., Miertus, J., Botta, G., Naretto, V.G., Janetzki, C., Yaqoob, N., Ott, C.E., Seelow, D., Wiczorek, D., Fiebig, B., Wirth, B., Hoopmann, M., Walther, M., Korber, F., Blankenburg, M., Mundlos, S., Heller, R. and Hoffmann, K. 2008, *Am. J. Hum. Genet.*, 82, 464.
28. Ohno, K., Engel, A.G., Brengman, J.M., Shen, X.-M., Heidenrich, F.R., Vincent, A., Milone, M., Tan, E., Demirci, M., Walsh, P., Nakano, S. and Akiguchi, I. 2000, *Ann. Neurol.*, 47, 162.
29. Croxen, R., Hatton, C., Shelley, C., Brydson, M., Chauplannaz, G., Oosterhuis, H., Vincent, A., Newsom-Davis, J., Colquhoun, D. and Beeson, D. 2002, *Neurology*, 59, 162.
30. Croxen, R., Newland, C., Beeson, D., Oosterhuis, H., Chauplannaz, G., Vincent, A. and Newsom-Davis, J. 1997, *Hum. Mol. Genet.*, 6, 767.
31. Engel, A.G., Ohno, K., Milone, M., Wang, H.L., Nakano, S., Bouzat, C., Pruitt, J.N., 2nd, Hutchinson, D.O., Brengman, J.M., Bren, N., Sieb, J.P. and Sine, S.M. 1996, *Hum. Mol. Genet.*, 5, 1217.
32. Wang, H.-L., Auerbach, A., Bren, N., Ohno, K., Engel, A.G. and Sine, S.M. 1997, *J. Gen. Physiol.*, 109, 757.
33. Vohra, B.P., Groshong, J.S., Maselli, R.A., Verity, M.A., Wollmann, R.L. and Gomez, C.M. 2004, *Ann. Neurol.*, 55, 347.
34. Ohno, K., Wang, H.-L., Shen, X.-M., Milone, M., Brengman, J.M., Bernasconi, L., Sine, S.M. and Engel, A.G. 2000, *Neurology*, 54 (Suppl 3), A183 (abstract).
35. Abdelgany, A., Wood, M. and Beeson, D. 2003, *Hum. Mol. Genet.*, 12, 2637.
36. Milone, M., Wang, H.L., Ohno, K., Fukudome, T., Pruitt, J.N., Bren, N., Sine, S.M. and Engel, A.G. 1997, *J. Neurosci.*, 17, 5651.
37. Shen, X.M., Deymeer, F., Sine, S.M. and Engel, A.G. 2006, *Ann. Neurol.*, 60, 128.
38. Gomez, C.M., Maselli, R., Staub, J., Day, J.W., Cens, T., Wollmann, R.L. and Charnet, P.C. 1998, *Soc Neurosci Abstr*, 24, 484 (abstract).
39. Gomez, C.M., Maselli, R., Gammack, J., Lasalde, J., Tamamizu, S., Cornblath, D.R., Lehar, M., McNamee, H. and Kuncl, R.W. 1996, *Ann. Neurol.*, 39, 712.
40. Shen, X.M., Ohno, K., Milone, M., Brengman, J.M., Tsujino, A. and Engel, A.G. 2003, *Mol. Biol. Cell*, 14 (Suppl), 223a (abstract).
41. Gomez, C.M., Maselli, R.A., Vohra, B.P., Navedo, M., Stiles, J.R., Charnet, P., Schott, K., Rojas, L., Keesey, J., Verity, A., Wollmann, R.W. and Lasalde-Dominicci, J. 2002, *Ann. Neurol.*, 51, 102.
42. Shelley, C. and Colquhoun, D. 2005, *J Physiol*, 564, 377.
43. Hatton, C.J., Shelley, C., Brydson, M., Beeson, D. and Colquhoun, D. 2003, *J Physiol*, 547, 729.
44. Shen, X.M., Ohno, K., Fukudome, T., Tsujino, A., Brengman, J.M., Engel, A.G., DeVivo, D.C. and Packer, R.J. 2002, *J. Neurol. Sci.*, 199 (Suppl 1), S96 (abstract).
45. Fidzianska, A., Ryniewicz, B., Shen, X.M. and Engel, A.G. 2005, *Neuromuscul. Disord.*, 15, 753.
46. Outteryck, O., Richard, P., Lacour, A., Fournier, E., Zephir, H., Gaudon, K., Eymard, B., Hantai, D., Vermersch, P. and Stojkovic, T. 2009, *J. Neurol. Neurosurg. Psychiatry*, 80, 450.
47. Ohno, K., Milone, M., Brengman, J.M., LoMonaco, M., Evoli, A., Tonali, P.A. and Engel, A.G. 1998, *Neurology*, 50 (Suppl. 4), A432 (abstract).
48. Gomez, C.M. and Gammack, J.T. 1995, *Neurology*, 45, 982.
49. Shen, X.-M., Ohno, K., Tsujino, A., Brengman, J.M., Gingold, M., Sine, S.M. and Engel, A.G. 2003, *J. Clin. Invest.*, 111, 497.

50. Webster, R., Brydson, M., Croxson, R., Newsom-Davis, J., Vincent, A. and Beeson, D. 2004, *Neurology*, 62, 1090.
51. Wang, H.-L., Milone, M., Ohno, K., Shen, X.-M., Tsujino, A., Batocchi, A.P., Tonali, P., Brengman, J., Engel, A.G. and Sine, S.M. 1999, *Nat. Neurosci.*, 2, 226.
52. Shen, X.M., Fukuda, T., Ohno, K., Sine, S.M. and Engel, A.G. 2008, *J. Clin. Invest.*, 118, 1867.
53. Brownlow, S., Webster, R., Croxson, R., Brydson, M., Neville, B., Lin, J.P., Vincent, A., Newsom-Davis, J. and Beeson, D. 2001, *J. Clin. Invest.*, 108, 125.
54. Ohno, K., Wang, H.-L., Milone, M., Bren, N., Brengman, J.M., Nakano, S., Quiram, P., Pruitt, J.N., Sine, S.M. and Engel, A.G. 1996, *Neuron*, 17, 157.
55. Shen, X.-M., Ohno, K., Milone, M., Brengman, J.M., R., S.P. and Engel, A.G. 2001, *Neurology*, 56 (Suppl 3), A60 (abstract).
56. Sine, S.M., Shen, X.-M., Wang, H.-L., Ohno, K., Lee, W.-Y., Tsujino, A., Brengman, J., Bren, N., Vajsar, J. and Engel, A.G. 2002, *J. Gen. Physiol.*, 120, 483.
57. Milone, M., Wang, H.-L., Ohno, K., Prince, R., Fukudome, T., Shen, X.-M., Brengman, J.M., Griggs, R.C., Sine, S.M. and Engel, A.G. 1998, *Neuron*, 20, 575.
58. Wang, H.-L., Ohno, K., Milone, M., Brengman, J.M., Evoli, A., Batocchi, A.P., Middleton, L.T., Christodoulou, K., Engel, A.G. and Sine, S.M. 2000, *J. Gen. Physiol.*, 116, 449.
59. Shen, X.-M., Ohno, K., Sine, S.M. and Engel, A.G. 2005, *Brain*, 128, 345.
60. Abicht, A., Stucka, R., Song, I.-H., Karcagi, V., Kugler, K., Baumgarten-Walczak, A., Stier, C., Pongratz, D., Mortier, W., Müller-Felber, W., Rüdell, R. and Lochmüller, H. 2000, *Acta Myologica*, 19, 23.
61. Groshong, J.S., Spencer, M.J., Bhattacharyya, B.J., Kudryashova, E., Vohra, B.P., Zayas, R., Wollmann, R.L., Miller, R.J. and Gomez, C.M. 2007, *J. Clin. Invest.*, 117, 2903.
62. Fucile, S., Sucapane, A., Grassi, F., Eusebi, F. and Engel, A.G. 2006, *J Physiol*, 573, 35.
63. Di Castro, A., Martinello, K., Grassi, F., Eusebi, F. and Engel, A.G. 2007, *J Physiol*, 579, 671.
64. Fukudome, T., Ohno, K., Brengman, J.M. and Engel, A.G. 1998, *Neuroreport*, 9, 1907.
65. Harper, C.M. and Engel, A.G. 1998, *Ann. Neurol.*, 43, 480.
66. Harper, C.M., Fukodome, T. and Engel, A.G. 2003, *Neurology*, 60, 1710.
67. Wirtz, P.W., Titulaer, M.J., Gerven, J.M. and Verschuuren, J.J. 2010, *Expert Rev Clin Immunol*, 6, 867.
68. Hesselms, L.F., Jennekens, F.G., Van den Oord, C.J., Veldman, H. and Vincent, A. 1993, *Anat. Rec.*, 236, 553.
69. Morgan, N.V., Brueton, L.A., Cox, P., Grealley, M.T., Tolmie, J., Pasha, S., Aligianis, I.A., van Bokhoven, H., Marton, T., Al-Gazali, L., Morton, J.E., Oley, C., Johnson, C.A., Trembath, R.C., Brunner, H.G. and Maher, E.R. 2006, *Am. J. Hum. Genet.*, 79, 390.
70. Hoffmann, K., Muller, J.S., Stricker, S., Megarbane, A., Rajab, A., Lindner, T.H., Cohen, M., Chouery, E., Adaimy, L., Ghanem, I., Delague, V., Boltshauser, E., Talim, B., Horvath, R., Robinson, P.N., Lochmuller, H., Hubner, C. and Mundlos, S. 2006, *Am. J. Hum. Genet.*, 79, 303.
71. Giraud, M., Taubert, R., Vandiedonck, C., Ke, X., Levi-Strauss, M., Pagani, F., Baralle, F.E., Eymard, B., Tranchant, C., Gajdos, P., Vincent, A., Willcox, N., Beeson, D., Kyewski, B. and Garchon, H.J. 2007, *Nature*, 448, 934.

CHAPTER 8

CONGENITAL MYASTHENIC SYNDROMES

Andrew G. Engel, M.D.^a
Shin-Ming Shen, Ph.D.^a
Kinji Ohno, M.D., Ph.D.^b
Steven M. Sine, Ph.D.^c

^aDepartment of Neurology and Neuromuscular Research Laboratory and ^cDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905; ^bDivision of Neurogenetics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Direct correspondence to Dr. Andrew Engel, Department of Neurology, Mayo Clinic, Rochester, MN 455905; Fax: 507-284-5831; Phone: 507-284-5102; E-mail: age@mayo.edu.

CHAPTER OUTLINE

HISTORIC INTRODUCTION

MECHANISMS COMPROMISING THE SAFETY MARGIN OF NEUROMUSCULAR TRANSMISSION

THE CLASSIFICATION OF CONGENITAL MYASTHENIC SYNDROMES

THE INVESTIGATION OF CONGENITAL MYASTHENIC SYNDROMES

Clinical Observations

HISTORY AND EXAMINATION

THE INTRAVENOUS EDROPHONIUM TEST

EMG STUDIES

SEROLOGIC TESTS

Morphology

ROUTINE HISTOCHEMICAL STUDIES

CYTOCHEMICAL LOCALIZATION OF AChE

IMMUNOCYTOCHEMICAL LOCALIZATION OF AChR AND OTHER ENDPLATE ASSOCIATED PROTEINS

ELECTRON MICROSCOPY AND ELECTRON CYTOCHEMISTRY

¹²⁵I- α -bgt Binding Sites Per Endplate

In Vitro Electrophysiology Studies

CONVENTIONAL MICROELECTRODE STUDIES

Molecular Genetic Studies

EXPRESSION STUDIES

PRESYNAPTIC CMS

CMS Caused by Defects in Choline Acetyltransferase (ChAT)

CLINICAL FEATURES

ELECTROPHYSIOLOGY

MORPHOLOGY

MOLECULAR STUDIES

TREATMENT

Paucity of Synaptic Vesicles and Reduced Quantal Release

Congenital Myasthenic Syndrome Resembling the Lambert-Eaton Syndrome

SYNAPTIC BASAL-LAMINA-ASSOCIATED CMS

Endplate Acetylcholinesterase Deficiency

CLINICAL ASPECTS

ELECTROPHYSIOLOGY FEATURES

MORPHOLOGY

PATHOPHYSIOLOGY

MOLECULAR PATHOGENESIS

DIAGNOSIS

THERAPY

Defects in β 2-Laminin

POSTSYNAPTIC CMS

CMS Caused By Mutations in AChR

Slow-Channel Syndromes

CLINICAL ASPECTS

ELECTROPHYSIOLOGY FEATURES

MORPHOLOGY
 PATHOPHYSIOLOGY
 MOLECULAR GENETIC STUDIES
 DIAGNOSIS
 THERAPY

Fast-Channel Syndromes

CLINICAL ASPECTS
 ELECTROPHYSIOLOGY FEATURES
 MORPHOLOGY
 DIAGNOSIS
 THERAPY

AChR Deficiency Caused by Recessive Mutations in AChR Subunits

CLINICAL FEATURES
 ENDPLATE STUDIES
 MOLECULAR PATHOGENESIS
 GENETIC HETEROGENEITY
 THERAPY

Escobar Syndrome

CMS Caused by Defects in Rapsyn

CLINICAL FEATURES
 ELECTROPHYSIOLOGY
 MORPHOLOGY
 MOLECULAR FEATURES
 DIAGNOSIS
 THERAPY

DEFECTS IN MECHANISMS GOVERNING ENDPLATE DEVELOPMENT AND MAINTENANCE

CMS Caused by Defect in Agrin

CMS Caused by Defects in MuSK

CMS Caused by Defects in Dok-7

CLINICAL FEATURES AND RESPONSE TO THERAPY
 MORPHOLOGY
 ELECTROPHYSIOLOGY
 MOLECULAR STUDIES

CMS Caused by Defects in the Hexosamine Biosynthetic Pathway

Sodium Channel Myasthenia

CMS Caused by Plectin Deficiency

CMS Associated with Centronuclear Myopathy (CNM)

HISTORIC INTRODUCTION

Congenital myasthenic syndromes (CMS) are neither new nor uncommon disorders. In 1937, Rothbart¹ described four brothers under the age of 2 years with a myasthenic disorder, and by 1972 Sarah Bunday² was able to collect 97 familial cases of myasthenia with onset before the age of 2 years. After the discovery of the autoimmune origin of myasthenia gravis (MG) in the 1970s and of the Lambert-Eaton syndrome in the 1980s, it became apparent that myasthenic disorders occurring in a familial or congenital setting must have a different pathogenesis.³ In the 1970s and 1980s, ultrastructural, cytochemical, and in vitro microelectrode studies of CMS patients revealed a heterogeneous group of disorders: a presynaptic syndrome associated with a paucity of synaptic vesicles and decreased evoked release of acetylcholine (ACh) quanta;⁴ a presynaptic disease caused by a defect in the resynthesis or vesicular packaging of ACh;^{5,6} synaptic acetylcholinesterase (AChE) deficiency;⁷ and two postsynaptic syndromes, one attributed to slow closure of the acetylcholine receptor (AChR) ion channel,⁸ and one associated with AChR deficiency.^{9,10}

During the past two decades, further developments resulted in better understanding of previously identified CMS and new types of CMS were discovered. The primary sequences of several genes encoding key endplate associated proteins were determined; discovery of the crystal structure of the molluscan ACh binding protein and cryoelectron microscopy investigation of the atomic structure of Torpedo AChR provided a structural models for the binding^{11,12} and pore¹² domains of the receptor; patch clamping of human intercostal muscles endplates (EPs) to allow recording and analysis of single channel currents of the AChR was accomplished;¹³ and mammalian expression systems were used for detailed analysis of the consequences of mutations in endplate associated proteins.

MECHANISMS COMPROMISING THE SAFETY MARGIN OF NEUROMUSCULAR TRANSMISSION

The postsynaptic depolarization caused by a by a single quantum of ACh released from nerve terminal gives rise to a miniature EP potential (MEPP); depolarization induced by a larger number of quanta released by a nerve impulse generates an EP potential (EPP). The amplitude of the EPP must exceed a critical threshold to activate voltage-sensitive sodium channels in and around the postsynaptic region and thereby generate a muscle fiber action potential. Neuromuscular transmission fails and a myasthenic disorder results when the EPP fails to reach this critical threshold. The safety margin of neuromuscular transmission is defined as the difference between the amplitude of the EPP and the amplitude of the depolarization required to trigger a muscle fiber action potential.

In each CMS, the safety margin of neuromuscular transmission is compromised by one or more mechanisms. These mechanisms involve the synthesis or packaging of ACh quanta into synaptic vesicles, the Ca²⁺-dependent evoked release of ACh from the nerve terminal, and the efficiency of released quanta in generating a postsynaptic depolarization. Quantal efficiency depends on the EP geometry, the density and functional state of acetylcholinesterase (AChE) in the synaptic space, and the density, affinity for ACh, and kinetic properties of AChR.

THE CLASSIFICATION OF CONGENITAL MYASTHENIC SYNDROMES

Congenital myasthenic syndromes are classified as presynaptic, synaptic basal lamina associated, or postsynaptic according to the site of the primary defect. Table 1 presents a classification for CMS based on 306 index patients investigated at the Muscle Research Laboratory of the Mayo Clinic. In all but 3 of these patients the genetic basis of the CMS was determined. The classification is still tentative, as future studies are likely to provide further information on the

nature of presynaptic defects, some CMS are still incompletely characterized, and additional CMS are likely to be discovered. Inspection of Table 1 indicates that 80% of the CMS are postsynaptic, 14% are accounted for by EP AChE deficiency, and only 6% are presynaptic.

THE INVESTIGATION OF CONGENITAL MYASTHENIC SYNDROMES

A full understanding of how the safety margin of neuromuscular transmission is compromised in a given CMS is based on clinical, morphologic, in vitro electrophysiologic, and molecular genetic studies (Table 2). The clinical evaluation must include detailed electromyographic (EMG) and serologic studies. The morphologic evaluation should include careful examination of the fine structure of the EP. The in vitro electrophysiologic studies must be sufficiently complete so they provide information on parameters of quantal release and the factors affecting the efficiency of the released quanta. A surprising number of CMS stem from a kinetic abnormalities of the AChR. These can be recognized by examination of the decay phase of the miniature EP current (MEPC), and more accurately by patch-clamp analysis of currents flowing through single AChR channels. Since 1994, genetic analysis has become an important facet of CMS investigations.

Because only few medical centers are able to perform all or some of the above studies, mutations analysis of DNA isolated from blood or other tissues has been increasingly used to identify CMS disease genes. Targeted mutation analysis became feasible after it was realized that distinct clinical and EMG phenotypes can point to the disease gene. However, these phenotypes are often nonspecific; detection of a single or even two recessive variant in an endplate related gene of a CMS patient does not establish that the disease gene has been correctly identified, even if the mutation is not present in 200-400 normal control alleles; and in silico evaluation of the significance of a mutation is not consistently reliable or can be misleading. Given these caveats, if the clinical data provides no clues for targeted mutation analysis, one can still search mutations in endplate proteins in descending order of their currently known relative frequency in different, as shown in Table 1. Importantly, taking all CMS mutations identified in our laboratory, 53% were in subunits of AChR. Moreover, 34% of all observed mutations were low expressor mutation in the ϵ subunit whereas only 3% of the low-expressor mutations were detected in the α , β , or δ subunits of AChR.

Clinical Observations

HISTORY AND EXAMINATION

A typical clinical history for CMS is one of ocular, bulbar, or respiratory muscle symptoms worsened by crying or activity in the neonatal period; fluctuating ocular palsies and abnormal fatigability on exertion during infancy and childhood; normal or delayed motor milestones; sometimes progression of symptoms during adolescence or adult life; and negative tests for anti-antibodies directed against AChR, MuSK, and the P/Q type voltage-gated calcium channel. Some syndromes (e.g., the slow channel syndrome⁸ and familial limb-girdle myasthenia) may not present until the second or third decade of life; and in patients with choline acetyltransferase (ChAT) deficiency, the symptoms can be episodic, with severe weakness and respiratory insufficiency appearing with fever, excitement, or without known cause.^{5,6} A positive family history is consistent with the diagnosis. A negative family history does not exclude autosomal recessive inheritance, parental mosaicism for a dominant mutation, or one parent being hemizygous for a dominant gene mutated in the other parent.

On examination, the most important clue to a defect of neuromuscular transmission is increasing weakness on sustained exertion. This can be documented by observing increasing ptosis during sustained upward gaze, measuring the arm elevation time, counting the number of deep knee bends the patient can perform, or by repeated manual testing of selected muscles at short

intervals. Patients with severe involvement of the trunkal muscles, as in EP AChE deficiency or in the slow-channel syndrome, rapidly develop postural scoliosis and shift their weight from one foot to another on standing.¹⁴ Selectively severe weakness of cervical and of wrist and finger extensor muscles is found in older patients with EP AChE deficiency¹⁴ and in the slow-channel syndrome.⁸ Pupillary light reflexes are delayed in patients with EP AChE deficiency.¹⁴ Ocular muscle involvement can be absent or mild in some cases of EP AChE deficiency,¹⁴ the slow-channel syndrome,⁸ rapsyn deficiency, or limb-girdle myasthenia caused by mutations in Dok-7,¹⁵ or other genes. The tendon reflexes are preserved but are hypoactive or absent in a CMS resembling the Lambert-Eaton syndrome, in some cases of EP AChE deficiency,¹⁴ and in severe cases of the slow-channel syndrome.⁹ Table 3 lists the differential diagnoses of CMS. Most entities can be excluded by careful physical examination that reveals weakness increased by exertion and by demonstration of a decremental EMG response.

THE INTRAVENOUS EDROPHONIUM TEST

The test is negative in EP AChE deficiency and can be negative between spells of weakness in ChAT deficiency, and usually negative or inconsistently positive in the slow-channel syndrome and Dok-7 myasthenia. A negative edrophonium test does not exclude the diagnosis of a CMS; a positive test can be consistent with the diagnosis but does not differentiate it from autoimmune MG.

EMG STUDIES

Diagnosis of a CMS must be supported by a decremental EMG response at low-frequency (2-3 Hz) stimulation in at least one muscle, or by abnormal jitter and blocking during single fiber EMG. The decremental response can be absent in patients with ChAT deficiency when asymptomatic. In this case, the decremental response is elicited by 10 Hz stimulation for 5 to 10 minutes or by exercise for several minutes before stimulation.^{5,6}

In patients taking high doses of AChE inhibitors, in patients with EP AChE deficiency,^{7,14} and in the slow-channel syndrome,⁸ single nerve stimuli evoke a primary compound muscle action potential (CMAP) followed by one or more repetitive CMAPs, each separated by an interval of 5 to 8 ms. The repetitive potentials are smaller and decrement faster than the primary response at all frequencies of stimulation. Therefore, the test must be done in patients not exposed to AChE inhibitors, after a period of rest, and initially with single nerve stimuli.

Observations in the EMG laboratory can provide an objective estimate of responsiveness to AChE inhibitors or other cholinergic agents. For example, one can compare the decrement observed in a given muscle before and 30 minutes after a subcutaneous dose of neostigmine methylsulfate, or 60 to 90 minutes after an oral dose of 3,4-diaminopyridine (3,4-DAP).

SEROLOGIC TESTS

A positive AChR antibody test excludes the diagnosis of a CMS but a negative antibody test does not confirm it because some patients with autoimmune MG are also seronegative. Seronegative MG can sometimes be excluded by other findings. Absence of immune deposits (IgG and complement) from the EP, or an in vitro electrophysiologic abnormality different from that in MG, is strong evidence against seronegative MG.

Morphology

ROUTINE HISTOCHEMICAL STUDIES

These may show no abnormality or only type 2 fiber atrophy. In patients with postsynaptic CMS, there is frequently type 1 fiber preponderance. Type 1 fiber preponderance is not specific but when combined with type 2 fiber atrophy it suggests the diagnosis of a postsynaptic CMS.

In patients with the slow-channel syndrome, small groups of atrophic fibers and various myopathic alterations, including tubular aggregates and vacuolar changes near the endplate, occur in severely affected muscles.⁸ Tubular aggregates also appear in one type of limb-girdle CMS.

The mean muscle fiber diameter must be determined in all muscle specimens used for MEPP measurements, as the MEPP amplitude is related by an inverse exponential function to the fiber diameter.¹⁶

CYTOCHEMICAL LOCALIZATION OF AChE

EP AChE is concentrated in the basal lamina of the primary and secondary synaptic clefts.¹⁷ The light microscopic localization of AChE reveals the position and configuration of the synaptic gutter but provides no information on the pre- or postsynaptic components of the EP. When AChE is localized on fixed and teased fibers and the EP is viewed face-on, the normal synaptic gutter has an oval outline and branches like arms, resembling a pretzel. In the slow-channel syndromes, where the postsynaptic regions are destroyed by cationic overloading,^{8,9} in autoimmune MG,¹⁸ and in CMS caused by mutations that curtail AChR expression,¹⁹ the EPs are remodeled due to sprouting of terminal or ultraterminal axons and formation of new endplate regions. The AChE reaction now reveals multiple small EP regions dispersed over an extended length of the muscle fiber surface. Inaccurately, this is sometimes described as "elongation" of the EP and the axial length of the fiber surface on which AChE-positive zones are dispersed is designated as "the length of the endplate".^{18,20}

In congenital EP AChE deficiency, there is no reaction for AChE in either fresh or fixed muscle.^{7,14} When this diagnosis is suspected, AChE should be localized in the presence of 10^{-5} M iso-OMPA to inhibit any butyrylcholinesterase activity at or near the EP.

IMMUNOCYTOCHEMICAL STUDIES

Immunocytochemical studies have many uses. They can (1) reveal an absence of immunoreactive AChE in EP AChE deficiency;¹⁴ (2) prove or disprove the diagnosis of autoimmune MG by showing presence or absence of immune deposits (IgG, C3, and the C5b-9 membrane attack complex) at the EP; (3) provide a qualitative estimate of the abundance of AChR,^{9,21,22} at the EP; and (4) demonstrate presence, absence, or reduced expression of other EP-specific proteins, for example, the vesicular ACh transporter, synapsin 1, and ChAT in the nerve terminal; and Dok-7,¹⁵ agrin, rapsyn,²³ plectin, $\text{Na}_v1.4$,²⁴ and utrophin in the postsynaptic region. Subunit-specific anti-AChR antibodies can reveal absence of the adult-type ϵ subunit and reappearance of the fetal-type γ subunit of AChR at the EPs.^{9,21} However, immunocytochemical localizations are not helpful when a mutation does not decrease expression of the mutant protein,²⁴ or when a monoclonal antibody is directed against an epitope upstream of a truncating mutation.¹⁵

ELECTRON MICROSCOPY AND ELECTRON CYTOCHEMISTRY

Electron microscopy analysis of the EP is essential in the investigation of novel CMS. The size and density of the synaptic vesicles, the size of the nerve terminal and its relation to the Schwann cell, the structure of the junctional folds, and alterations in organelles of the junctional sarcoplasm cannot be observed in any other way. Quantitative electron microscopy allows morphometric reconstruction of the endplate,²⁵ yields data for structure-function correlations, and can point to the mechanism that impairs neuromuscular transmission. For example: (1) electron microscopy is required to demonstrate the paucity of synaptic vesicles in a unique CMS associated with reduced quantal release.⁴ Without visualizing the synaptic vesicles, this disorder could be confused with the Lambert-Eaton syndrome. (2) In endplate AChE deficiency, smallness of the nerve terminals and their encasement by Schwann cells explains the decrease in quantal release by nerve impulse.^{7,14}

(3) In the slow-channel syndrome, the degeneration of the junctional folds explains the loss of AChR and the reduced MEPP amplitude.^{8,26}

Electron cytochemical localization of AChR with peroxidase-labeled α -bungarotoxin (α -bgt) or with anti-AChR antibodies displays the density and distribution of AChR over the postsynaptic membrane.^{21,22,25,27,28} This information, together with the MEPP amplitude and the number of α -bgt binding sites per EP (see below), helps to assess the extent, significance, and mechanism of EP AChR deficiency.

¹²⁵I- α -bgt Binding Sites Per Endplate

This test is performed by incubating fine strips of muscle intact from origin to insertion in an oxygenated solution containing ¹²⁵I- α -bgt of known specific activity. After adequate rinsing, the strips are fixed and the EPs visualized by reacting them for AChE. After counting the EPs, the strips are divided into EP-positive and EP-negative segments of equal length and the radioactivity of the segments is measured in a gamma counter. The number of toxin molecules bound per endplate is then calculated from the difference in radioactivity between the EP-positive and EP-negative segments, the number of EPs, and the specific activity of the labeled toxin.

Two toxin molecules bind to each AChR. The number of toxin binding sites per EP, or N , is the product of the $A_T \times D$, where A_T is the total postsynaptic membrane area that binds toxin, and D the average density (number per unit area) of binding sites. In infants and young children, N is smaller than in adults because the EPs, and therefore A_T , are smaller than in adults. In adults with endplates of normal shape and size, a decrease in N argues for a decrease in D . In diverse CMS, a decrease of N is associated with the appearance of multiple small EP regions over an extended span of the fiber surface.^{19,21,22,26} Here the decrease must involve either A_T or D . (When N is reduced, D could be reduced and A_T reduced, normal, or increased; or D could remain constant while A_T is reduced.) Depending on the etiology, ultrastructural localization of peroxidase-labeled α -bgt at such EPs shows either a diffuse decrease of AChR over intact junctional folds^{19,21,22} or a focal loss of AChR from degenerating folds.²⁶

In Vitro Electrophysiology Studies

CONVENTIONAL MICROELECTRODE STUDIES

A muscle specimen intact from origin to insertion is obtained from an intercostal²⁹ or the anconeus muscle³⁰ and the amplitude, frequency, and decay time constants of the MEPP and MEPC as well as parameters of evoked quantal release are routinely determined.

Potentials are recorded from rested muscle with focally placed microelectrodes and their amplitude is normalized for a resting membrane potential of -80 mV. Potentials >3 mV are also corrected for nonlinear summation as described by Martin.³¹ The MEPP amplitude is affected by the cable properties of the sarcolemma,¹⁶ the number of ACh molecules per quantum, end-plate geometry, and the density and kinetic properties of AChR.^{32,33} With AChE intact, the decay phase of the MEPP is related to the open time of the AChR channel^{34,35} and the cable properties of the sarcolemma.^{16,36} In children, the small diameter of the muscle fiber increases the input resistance of the fiber. In this case, the MEPP amplitude is corrected by the factor $(D_o/55)^{3/2}$, where D_o is the observed fiber diameter and 55 represents the normal mean adult fiber diameter in μm .¹⁶

The MEPC is recorded from the voltage-clamped muscle fiber. It is independent of the cable properties of the sarcolemma but otherwise is affected by the same factors as the MEPP.³⁷ The amplitude and duration of the MEPC are the macroscopic expression of the bursts of AChR channel activity occurring in response to one quantum of ACh.³⁸ With EP AChE intact, the decay time constant of the MEPC reflects, but is usually somewhat longer than, the mean burst duration.

The number of quanta released by a nerve impulse (m) is determined at 1 Hz stimulation.^{31,39,40} When nerve stimulation causes the preparation to twitch, suitable amounts of curare are added to the bath. The 7th to 70th EPP is recorded from a train of 70 and m is calculated by the variance method, in which

$$m = (\text{EPP}_m)^2 / \text{EPP}_V \quad (1)$$

where EPP_m and EPP_V are the mean and variance of the corrected EPP amplitudes,⁴⁰ or by the failures method, in which

$$m = \ln(\text{impulses/failures}) \quad (2)$$

When the amplitude of the EPP is subthreshold for eliciting a muscle fiber action potential, no curare is added to the bath and m can be obtained by the ratio method, in which

$$m = \text{EPP}_m / \text{MEPP}_m \quad (3)$$

When m exceeds 8 and is obtained from equations 1 or 2, it is also corrected for deviation from Poisson statistics by the empiric formula

$$m_c = 1.743 \times (m_o)^{0.733} \quad (4)$$

where m_c and m_o are the corrected and observed values of m .^{41,42}

The value of m is affected by the probability of quantal release (p) and the number of readily releasable quanta (n), according to the formula $m = np$.^{29,39} Therefore, p and n are also determined using brief trains of high-frequency stimuli.⁴³ The value of p is related to the calcium concentration within the nerve terminal. Under the experimental conditions, at a given EP n is affected by the total nerve terminal volume, the synaptic vesicle density, recruitment of synaptic vesicles to the readily releasable pool, priming of the vesicles for release, and the presynaptic membrane area available for vesicle exocytosis.

PATCH-CLAMP RECORDINGS

High resolution patch-clamp recordings of currents flowing through single AChR channels provide precise information on channel conductance and on the kinetic properties of the AChR.^{19,26,44-49} Patch-clamp recordings, however, reflect the response of a limited number of channels to a fixed concentration of ACh at steady state whereas the MEPC reflects the instantaneous response to a pulse ACh at saturating concentration, and the opening probabilities of the AChR channel under the two conditions are different.²²

Whole-cell patch-clamp recordings are useful in analysis of desensitization and ionic permeabilities of AChR. These recordings cannot be obtained at the EP but can be performed on fibroblasts transfected with wild-type or mutant AChRs.

Molecular Genetic Studies

Mutation analysis is greatly facilitated when the physiologic or morphologic studies point to a candidate protein whose primary sequence is known. For example, a kinetic abnormality of AChR detected at the single channel level,^{26,28,45,46,50} or severe deficiency of AChR revealed by ¹²⁵I- α -bgt binding studies,^{19,21,51} predicts one or two mutations in an AChR subunit gene. Absence of AChE from the EP predicts a mutation in the catalytic or collagenic tail subunit of the asymmetric form of AChE.⁵² A predominantly limb-girdle distribution of weakness suggests a mutation in *DOK7*, *RAPSN*, or *GFPT1*. Sudden episodes of apnea point to a mutation in *CHAT*,⁵³ *RAPSN*,²³ *SCN4A*.²⁴ The pathogenicity of the mutations identified by the candidate protein approach is confirmed by cosegregation of the mutations with disease in the investigated kinship, absence of the identified variant from at least 200 alleles of 100 control subjects, and by expression studies in human embryonic kidney (HEK) cells,⁵⁴ *Xenopus* oocytes, monkey kidney fibroblasts (COS cells),⁵² or mouse myotubes.¹⁵

When no candidate genes are apparent, mutation analysis can be based on frequencies of

the heretofore identified mutations in different endplate proteins, as shown in Table 1. This approach is more expensive and time intensive than the candidate gene approach. In our experience, about one-third of the DNA samples analyzed in this manner reveal no mutations.

Another approach is linkage analysis if a sufficient number of informative relatives are available. If successful, it will point to a candidate chromosomal locus. If the physical map of the locus shows an attractive candidate gene, then mutation analysis by direct sequencing becomes feasible. This approach seldom works for CMS because large informative CMS kinships are seldom available except for inbred populations with multiple consanguineous families,

A novel approach to mutation discovery is exome sequencing that searches for mutations in exons. Kits available for this method presently capture ~97% of the entire exome but read only 75% of the exome with more than 20x coverage and miss changes in noncoding DNA. The enormous amount of generated data need to be filtered against previously identified variants deemed nonpathogenic and selecting for mutations in genes that encode endplate related genes. The putative pathogenic mutations must still be confirmed by capillary sequencing and the pathogenicity of novel non-truncating mutations needs to be confirmed by expression studies. Moreover, exome sequencing is less efficient in detecting dominant than recessive mutations and is still very expensive. Sequencing the whole genome is also feasible but is even more expensive and more complicated to interpret than exome sequencing.⁵⁵

A more direct and efficient approach is to use microarrays specifically designed for screening multiple candidate disease loci in known CMS genes. One publication finds this approach has a 73.3% overall sensitivity and a 95.5% sensitivity for missense mutation, but it is not recommended for detecting insertion or deletion mutations.⁵⁶ Also, this approach will miss mutations in novel CMS disease genes.

EXPRESSION STUDIES

Once a mutation is identified and its pathogenicity confirmed, expression studies can provide information on how the mutation affects the level of expression, kinetic properties, and interaction of the mutant protein with other molecules. For example, coexpression of AChR subunit mutants with complementary wild-type subunits in HEK cells identifies null and low-expressor mutations, reveals whether the mutation interferes with subunit assembly, and shows how a mutation can affect the kinetic steps of receptor activation.^{28,57} Coexpression of the collagenic tail mutants AChE with wild-type catalytic AChE subunits in COS cells demonstrates that the mutations prevent association of the tail subunit with the catalytic subunits, or prevents expression or assembly of the triple helical tail subunit required for insertion of the enzyme into the synaptic basal lamina.⁵²

PRESYNAPTIC CMS

CMS Caused by Defects in Choline Acetyltransferase (ChAT)

CLINICAL FEATURES

The clinical features of this disorder were recognized more than five decades ago under the rubric of "familial infantile myasthenia",⁵⁸ but it was not differentiated from MG until the autoimmune origin of MG was established and electrophysiologic and morphologic differences were demonstrated between MG and the congenital syndrome.^{5,6,59} Because the distinguishing clinical feature is *sudden and unexpected episodes* of severe dyspnea and bulbar weakness culminating in apnea, the disease has also been referred to as CMS with episodic apnea (CMS-EA). Initial studies of the clinical syndrome revealed no endplate AChR or AChE deficiency but suggested impaired resynthesis or vesicular packaging of ACh.^{5,6}

Some patients present with hypotonia, bulbar paralysis and apnea at birth. Most patients gradually improve but still have variable ptosis, ophthalmoparesis, intermittent respiratory

difficulty and recurrent cyanotic episodes, some requiring resuscitation, during infancy and later life precipitated by infections, fever, excitement, or occurring with no apparent cause (Fig. 8-8-1). Few patients remain apneic and paralyzed since birth and some develop cerebral atrophy after episodes of hypoxemia.^{60,61} Other patients are normal at birth and develop apneic attacks during infancy or childhood.^{53,60-67} Some children after an acute attack experience respiratory insufficiency that may last for weeks.⁶⁸ Some patients are worsened by exposure to cold probably due to further decrease of the catalytic efficiency of the mutant enzyme at a lower temperature.⁶³ Between episodes of worsening, some patients appear normal or have only mild to moderate myasthenic symptoms. When weakness is absent, it can be readily induced by exercise. In the milder cases the crises become less frequent with age. After age 10, some patients only complain of easy fatigability on sustained exertion; others have mild to moderate weakness of cranial, limb, and respiratory muscles even at rest, resembling patients with mild to moderately severe autoimmune MG. The tendon reflexes remain normally active.^{6,58,69-71} The disease is transmitted by autosomal recessive inheritance.⁵⁹

Phenotypic heterogeneity can occur within a given kinship⁶² or in unrelated patients carrying identical mutations.⁶⁵ Intrafamily phenotypic variability is illustrated by a kinship in which two sibs died suddenly at 2 and 11 months of age during febrile episodes; one was asymptomatic and the other had only mild ptosis prior to death. A third sibling began having abrupt episodes of dyspnea and cyanosis at age 14 months precipitated by fever or vaccination; at age 32 months, she developed ptosis and abnormal fatigue on exertion which lead to the diagnosis of a myasthenic disorder.⁶²

ELECTROPHYSIOLOGY

A decremental response at 2 Hz stimulation and single fiber EMG (SFEMG) abnormalities are generally detected only when the tested muscles are weak. Weakness and EMG abnormalities consisting of a decrease of the CMAP to below 50% of the baseline and appearance of a decremental response at 2 Hz can be induced in some but not all muscles either by exercise or by subtetanic stimulation at 10 Hz for 5 to 10 minutes which is followed by *slow recovery* over 10 minutes or longer.^{5,6,59,60} A marked decline of the CMAP during subtetanic stimulation also occurs in patients in other types of CMS but here the CMAP returns to the baseline within 1 to 2 min. Except in the most severely affected patients, the EMG decrement, *when present*, can be corrected by edrophonium.⁷⁰

In vitro studies on intercostal muscle EPs elucidated the electrophysiologic basis of the disorder.^{5,6,59} The MEPP amplitude is normal in the rested state, but it decreases abnormally after 10 Hz stimulation for 5 min. The amplitude of the EPP also decreases abnormally during 10-Hz stimulation and then recovers *slowly* over the next 10 to 15 minutes (Fig. 8-2) whereas the quantal content of the EPP is essentially unaltered.^{6,62}

MORPHOLOGY

Muscle biopsy specimens show no histochemical abnormality. The number of AChRs per endplate and postsynaptic ultrastructure are normal, but morphometric analysis indicates that the synaptic vesicles are smaller than normal in rested muscle.⁶ The density and distribution of AChR on the junctional folds and the number of ¹²⁵I- α -bgt binding sites per EP are normal.^{6,59}

MOLECULAR STUDIES

The slow recovery of the synaptic response to ACh after subtetanic stimulation pointed to a defect in the resynthesis or vesicular packaging of ACh and implicated four candidate genes: the presynaptic high-affinity choline transporter,^{72,73} ChAT,⁷⁴ the vesicular ACh transporter

(VACHT)⁷⁵ and the vesicular proton pump.⁷⁶ In 2001, mutation analysis in 5 patients with characteristic clinical and EMG findings uncovered no mutations in *VACHT* but revealed 10 recessive mutations in *CHAT* that altered the expression or kinetic properties of the enzyme.⁵³ Subsequently similar clinical clues enabled different investigators to identify additional patients harboring *CHAT* mutations,^{60,61,63-67} but none of these studies⁶⁰ examined the expression or kinetic properties of the mutant enzymes. In 2004, the atomic structural model of human ChAT was solved at 2.2 Å resolution^{77,78} and kinetic effects of the mutations could now be related to their proximity to the substrate binding and catalytic sites of ChAT. Fig. 8-3A shows an atomic structural model of human ChAT and 12 missense and 1 nonsense mutation recently identified in our laboratory. Alone or in combination, the missense mutations alter the turnover rate, substrate affinity, substrate dissociation constant, or catalytic efficiency of ChAT, or render the enzyme conformationally unstable. Missense mutations positioned near the active site tunnel or the substrate binding sites of the enzyme have the most severe kinetic consequences⁶⁰ (See Fig. 8-3).

Patients harboring ChAT mutations have no autonomic symptoms or signs of central nervous system involvement other than attributable to anoxia. This cannot be due to ChAT having an EP-specific isoform because the observed mutations occur in the common coding region of all known ChAT isoforms. A possible explanation is that the ChAT level or substrate availability in the nerve terminal render ChAT rate limiting for ACh synthesis during physiologic activity at the EP but not at other cholinergic synapses. That stimulated quantal release at the EP is higher than at other cholinergic synapses likely contributes to selective vulnerability of the EP to reduced ACh resynthesis.

It is also important to note that defects in the presynaptic high-affinity choline transporter,^{72,73} the vesicular ACh transporter,⁷⁵ or the vesicular proton pump,⁷⁶ could also curtail ACh resynthesis and result in similar clinical and EMG phenotypes, but no mutations of these proteins have been detected to date.

TREATMENT

Except in the few most severely affected patients, anticholinesterase medications benefit patients with myasthenic symptoms between respiratory crises, and prevent or mitigate the crises. Therefore prophylactic anticholinesterase therapy is advocated even for patients who are asymptomatic between crises. Some severely affected patients with permanent apnea and severe weakness that fail to respond to therapy harbor at least one mutation with severe kinetic consequences (Fig. 8-3B).

Parents of affected children must be indoctrinated to anticipate sudden worsening of the weakness and possible apnea with febrile illnesses, excitement, or overexertion. They also should be able to administer appropriate doses of prostigmine or pyridostigmine intramuscularly, and use an inflatable rescue bag with a fitted mask in a crisis and during transport to hospital. Long-term nocturnal apnea monitoring is indicated in any patient in whom ChAT deficiency is proven or suspected.⁶²

Paucity of Synaptic Vesicles and Reduced Quantal Release

In this rare congenital myasthenic syndrome, the safety margin of neuromuscular transmission is compromised by the paucity of synaptic vesicles in the nerve terminal. The first instance of this disease was observed by us in 1989 in a 23-year-old woman with fatigable weakness of the bulbar and limb muscles since infancy⁴ (Fig. 8-4). The symptoms responded to anticholinesterase drugs. Tests for anti-AChR antibodies were negative. A decremental EMG response was present at 2 Hz stimulation. In vitro microelectrode studies revealed that the quantal content of the EPP (m) was markedly reduced due to a decrease in the number of readily releasable quanta (n); the probability

of quantal release (p) was normal. The amplitude and the decay time constant of the MEPP were normal. Two observations indicated that the presynaptic voltage sensitive calcium channels functioned normally: (1) increased calcium concentration in the bath in which the excised muscle strips were incubated increased m normally and (2) increased potassium concentration in the bath increased the MEPP frequency normally. The number of AChRs per EP, estimated from the number of ^{125}I - α -bgt binding sites, was normal. Quantitative ultrastructural studies of unstimulated EPs demonstrated an approximately 80% decrease in synaptic vesicle density (no./ μm^2) (Fig. 8-5), which was comparable to the decrease in n . Nerve terminal size, presynaptic membrane length, and the postsynaptic region were normal by ultrastructural criteria. A second patient with elements of the same disease was reported in an abstract in 1994 but the mutant protein was not identified.⁷⁹

This syndrome superficially resembles the Lambert-Eaton myasthenic syndrome (LEMS) in that m is reduced in both, but unlike in LEMS (1) the amplitude of the initial compound muscle action potential (CMAP) is not reduced, (2) the CMAP does not facilitate appreciably at high rates of repetitive stimulation, (3) the decrease in m is due to a decrease in n (and not in p , as in LEMS), (4) the voltage sensitive calcium channels of the nerve terminal are functionally normal, and (5) the decrease in n is associated with a proportionate decrease in the density of the synaptic vesicles.

Synaptic vesicle precursors associated with different sets of synaptic vesicle proteins are produced in the perikaryon of the anterior horn cell and are carried distally along motor axons to the nerve terminal by kinesin-like motors.⁸⁰⁻⁸³ Mature vesicles containing a full complement of vesicular proteins are assembled in the nerve terminal⁸³ and are then packed with ACh. After ACh has been released by exocytosis, the vesicle membranes are recycled and are repacked with ACh.⁸⁴ In the present syndrome the reduction in synaptic vesicle density could arise from (1) a defect in the formation of synaptic vesicle precursors in the anterior horn cell, (2) a defect in the axonal transport of one or more species of precursor vesicles, (3) impaired assembly of the mature synaptic vesicles from their precursors, or (4) impaired recycling of the synaptic vesicles in the nerve terminal. That synaptic vesicle density was reduced even in unstimulated nerve terminals argues against a defect in vesicle recycling.

Congenital Myasthenic Syndrome Resembling the Lambert-Eaton Syndrome

One young child was reported with this syndrome in 1987.⁸⁵ The CMAP amplitude was abnormally small but facilitated severalfold on tetanic stimulation, and the symptoms were improved by guanidine. A second patient observed at the Mayo Clinic was a 6-month-old girl with severe bulbar and limb weakness, hypotonia, areflexia, and respirator dependency since birth. The EMG showed a low-amplitude CMAP that facilitated 500% on high-frequency stimulation and decremented 40% on low-frequency stimulation. Studies of an anconeus muscle specimen revealed no EP AChR deficiency. Electron microscopy of the EPs showed structurally intact presynaptic and postsynaptic regions, no AChR deficiency, and abundant synaptic vesicles in the nerve terminals (Fig. 8-6). The MEPP amplitude was normal but the quantal content of the EPP, m , was less than 10% of normal at 1 Hz stimulation, and 40-Hz stimulation increased m by 300%. Thus, the in vitro electrophysiologic findings were like those in the Lambert-Eaton syndrome.⁸⁶ Although 3,4-DAP which increases the number of ACh quanta released by nerve impulse⁸⁷ improved the EMG abnormalities, the patient remained weak and respirator dependent. The molecular basis of this CMS could be due to a defect in the presynaptic voltage-gated calcium channel $\text{Ca}_v2.1$ or in a component of the synaptic vesicle release complex. Mutation analysis of *CACNA1A* that encodes the pore forming α_1 subunit of the $\text{Ca}_v2.1$ revealed no mutations.

SYNAPTIC BASAL-LAMINA-ASSOCIATED CMS

Defects in three components of the synaptic basal lamina, AChE, β_2 laminin and neural agrin,

are associated with CMS. This section considers the CMS caused by defects in AChE and β 2-laminin. The CMS caused by mutations in agrin will be discussed in conjunction with defects postsynaptic proteins required for aggregation and anchoring of AChR in the postsynaptic region.

Endplate Acetylcholinesterase Deficiency

The EP species of AChE is an asymmetric enzyme composed of homotetramers of catalytic subunits (AChE_T) and a collagenic tail subunit composed of three strands of ColQ. The tails subunit anchors the enzyme in the synaptic basal lamina.⁸⁸

CLINICAL ASPECTS

Human EP AChE deficiency was first recognized in 1977 in a boy with life-long myasthenic symptoms refractory to AChE inhibitors.⁷ AChE was absent from the endplates by enzyme cytochemical and immunocytochemical criteria, and electron cytochemical studies revealed no reaction product for the enzyme in the synaptic space. In most patients, weakness and abnormal fatigability are present since birth or early childhood and are highly disabling.^{14,52,89,90} In the more severely affected patients poor suck, cry, and episodes of respiratory distress occur in infancy and motor milestones are delayed. In less severely affected patients the disease presents in childhood and becomes disabling only in the second decade⁹¹⁻⁹³ or later in life.⁹⁰ The weakness affects the facial, cervical, axial, and limb muscles (Fig. 8-7). Ophthalmoparesis is present but not in all patients. The axial muscles are severely involved, so that on standing the patient may show increasing lordosis and scoliosis after a few seconds. Fixed scoliosis and severe weakness and atrophy of the dorsal forearm and intrinsic hand muscles occur in older patients. In few patients, however, the weakness has a limb-girdle distribution. The tendon reflexes can be normal or depressed. Some patients have an abnormally slow pupillary light reflex. Phenotypic heterogeneity with regard to age of onset, progression, and severity of symptoms has been documented within and between kinships carrying the homozygous G240X mutation⁹⁰ or heterozygous⁹⁴ *COLQ* mutations.

ELECTROPHYSIOLOGY

The EMG shows a decremental response at 2 Hz (Fig. 8-8A) and at higher frequencies of stimulation in all muscles. Most patients have a repetitive CMAP response on nerve stimulation. The repetitive CMAP decrements faster than the primary CMAP and disappears at stimulation frequencies greater than 0.2 Hz (Fig. 8-8A) or with mild activity. Therefore it can be overlooked unless a well rested muscle is tested by single nerve stimuli.

In vitro microelectrode studies of intercostal muscles show the MEPP and MEPC amplitudes to be normal or moderately reduced. However, absence of AChE from the EP predicts a higher than normal MEPP and MEPCs amplitude. This discrepancy can be attributed to degeneration of the junctional folds with loss of AChR. The decay time constants of the MEPPs, EPPs, and MEPCs (Fig. 8-8B) are prolonged two- to three-fold compared normal subjects. Consistent with the absence of AChE from the EP, prostigmine has no effect on the amplitude or decay of the EP potentials or currents.^{7,14} The quantal content of the EPP is markedly decreased due to a decreased number of releasable quanta (n); the probability of quantal release (p) is normal or higher than normal.^{7,14,52,90,95} Patch-clamp analysis of single-channel currents indicates that the conductance and kinetic properties of the AChR channel are normal.^{52,90}

MORPHOLOGY

Conventional histologic studies of muscle show type 2 fiber atrophy, or type 1 fiber preponderance, or both, or are normal. In most cases, AChE is absent from the endplate by light microscopic

criteria^{7,14,90} but traces of AChE appear in some patients with C-terminal mutations in ColQ.⁹¹ Electron cytochemical studies show no or only trace AChE in the synaptic cleft^{7,14} (Fig. 8-9) but at some EPs sparse reaction product for AChE appears in the junctional sarcoplasm. Immunoreactivity for AChE with polyclonal and several monoclonal AChE antibodies is absent or barely detectable.¹⁴

Electron microscopy reveals that many nerve terminals are abnormally small. Also, at many EPs Schwann cell processes extend into the primary synaptic cleft and partially or even completely occlude the presynaptic membrane, reducing the surface available for ACh release (Fig. 8-10). At some EPs the junctional folds are honeycombed by myriad pinocytotic vesicles and labyrinthine membranous networks (Fig. 8-11A). At other EPs, the junctional folds are degenerating and shed AChR-rich fragments into the synaptic space with loss of AChR (Figs. 8-10 and 11B). Some of the junctional nuclei are degenerating or apoptotic. (Fig. 8-11A) The total number of AChRs per EP is normal or reduced.

PATHOPHYSIOLOGY

Because AChE is absent from the EP, AChR-ACh interactions are terminated by diffusion of ACh from the synaptic space. Before leaving the synaptic space, ACh binds to several AChRs and this prolongs the decay phase of the EP potentials and currents.⁹⁶ The prolonged EPP triggers one or more additional muscle fiber action potentials if its amplitude remains above threshold when the muscle fiber recovers from the refractory period of the preceding action potential.

The reduced number of readily releasable quanta (n) is adequately accounted for by the smallness of the nerve terminal (see Fig. 8-11 A and B) and the reduced presynaptic membrane surface available for ACh release (see Fig. 8-10). However, the smallness of the nerve terminals and the decrease in n are not as constant as the AChE deficiency.

AChR is lost from the EPs with degeneration of the junctional folds. The degenerative changes can be attributed to cationic overloading of the postsynaptic region by the increased synaptic activity,^{97,98} but the EPs are partially protected from this by the restricted release of ACh quanta from the nerve terminal.

The safety margin is compromised by (1) smallness of n , (2) AChR deficiency, (3) desensitization of AChR from prolonged exposure to ACh during physiological activity,^{99,100} and (4) progressive depolarization of the postsynaptic region during physiological activity. The depolarization may be similar to that observed in organophosphate poisoning,¹⁰¹ arising from staircase summation of the prolonged EPPs at physiological rates of motor nerve firing. Progressive depolarization of the postsynaptic region inactivates the perijunctional voltage-sensitive sodium channels¹⁰² which blocks the generation of the muscle fiber action potential.

MOLECULAR PATHOGENESIS

The endplate species of AChE is an asymmetric enzyme composed of homotetramers of globular (G) catalytic subunits attached to a collagenic tail subunit.¹⁰³ The catalytic subunit has two carboxyl-terminal splice variants, AChE_T and AChE_H, expressed in muscle and erythrocytes respectively.¹⁰⁴ The collagenic tail subunit is formed by the triple helical association of three collagen-like strands, ColQ, encoded by *COLQ*, each of which can bind a homotetramer of AChE_T to form the asymmetric A₄, A₈, and A₁₂ moieties of the asymmetric enzyme¹⁰⁵ (Fig. 8-12A and B). Expression of globular and asymmetric forms of AChE in muscle, or in COS cells transfected with *ACHE_T* and *COLQ* cDNA, is readily monitored by density gradient centrifugation of tissue or cell extracts (Fig. 8-12C and D)

Conserved domains of ColQ include an N-terminal proline-rich attachment domain (PRAD) that associates with an AChE_T tetramer, a central collagen domain composed of GXY

triplets (where X and Y are any amino acids), and a C-terminal region enriched in charged residues and cysteines required for the assembly of the ColQ strands in a triple helix¹⁰⁶ (Fig. 8-12B). Anchorage of the asymmetric enzyme in the synaptic space is assured by two cationic heparan sulfate proteoglycan binding domains within the collagen domain¹⁰⁷ and by residues in the carboxyl-terminal domain.^{89,95} The tail subunit is anchored to the synaptic basal lamina by at least two binding partners: the heparan sulfate proteoglycan perlecan,¹⁰⁸ which in turn binds dystroglycan, and the extracellular domain of MuSK.¹⁰⁹ Association with these binding partners predicts close proximity of the extracellular asymmetric enzyme to the postsynaptic membrane. All naturally occurring mutations in the EP species of AChE observed to date reside in ColQ.

Numerous *COLQ* mutations have been identified to date^{52,90-92,94,95,110-112} (Fig. 8-12B). Four major types of mutations have been delineated by density gradient centrifugation analysis of extracts of COS cells cotransfected with cDNA of wild-type *ACHE_T* and mutant or wild type *COLQ*. (1) Mutations involving PRAD prevent attachment of *AChE_T* to ColQ and yield a sedimentation profile identical to that obtained after transfection with *ACHE_T* alone (Fig. 8-12E and I) indicating that mutant ColQ, if expressed, fails to bind catalytic subunits^{52,95} and no asymmetric AChE is formed. (2) Mutations that truncate the collagen domain prevent triple helical association of ColQ strands and give rise to an insertion incompetent truncated single strand of ColQ linked to an *AChE_T* tetramer that sediments as a distinct mutant peak at 10.5S^{52,95} (Fig. 8-12F and J). (3) A carboxyl-terminal mutant, 1082delC, produces a single-stranded insertion incompetent enzyme⁵² on account of 64 hydrophobic missense residues that follow the frame-shifting point mutation⁹⁵ (Fig. 8-12G and K, left). (4) Other C-terminal mutations produce either reduced (R315X)⁹² or normal amounts of the triple-helical asymmetric enzyme (Fig. 8-12H and K, right) which is generally insertion incompetent.⁸⁹

DIAGNOSIS

A lifelong history of weakness and fatigability of all muscles, a decremental EMG response at all frequencies of stimulation, and refractoriness to anticholinesterase drugs should suggest the diagnosis of EP AChE deficiency. A repetitive CMAP response to single nerve stimuli in a patient not exposed to anticholinesterase drugs indicates EP AChE deficiency or a slow-channel syndrome but is not seen in all patients. The diagnosis is established by showing that AChE is absent from all EPs by cytochemical or immunocytochemical criteria. In vitro electrophysiological studies can further confirm the diagnosis by demonstrating typical abnormalities of the endplate potentials and currents. Alternatively, the diagnosis can be established by mutation analysis of *COLQ*.

THERAPY

There is no satisfactory therapy for EP AChE deficiency. Anticholinesterase medications have no effect on neuromuscular transmission and can cause excessive muscarinic side effects. If the diagnosis of AChE deficiency is *not* suspected, refractoriness to an anti-AChE medication may prompt the physician to increase the dose; this, in turn, may result in excessive bronchial secretions and worsen the patient's clinical state. Quinidine or fluoxetine which shorten the open duration of the AChR channel and benefit the slow-channel syndrome,^{113,114} can cause increased weakness. Alternate-day prednisone therapy had a slight beneficial effect in two patients but was ineffective in one and appeared to worsen the symptoms in another. A respirator dependent infant with severe EP AChE deficiency was improved by intermittent blockade of AChR by atracurium, an agent that protects AChR from overexposure to ACh, allowing for temporary withdrawal of respiratory support.¹¹⁵ Ephedrine sulfate at a dose of 150 to 200 mg/day in adults has a markedly beneficial effect in some patients.^{93,112,116} Because ephedrine is no longer available in the US, the author has used oral albuterol sulfate, 8 to 16 mg per day in divided doses in adults with results

comparable to those of ephedrine. Vintage Pharmaceuticals suggests that dosing with albuterol sulfate in children 2 to 5 years of age should be initiated at 0.1 mg/kg of body weight three times a day. This starting dosage should not exceed 2 mg (1 teaspoonful of a syrup) three times a day.

Defect in β 2-Laminin

Laminins are cruciform heterotrimeric glycoproteins composed of a central α and flanking β and γ strands and are assembled from products of five α , four β , and three γ genes. The three identified laminins in synaptic basal lamina, laminin-4 (α 2 β 2 γ 1), laminin-9 (α 4 β 2 γ 1) and laminin-11 (α 5 β 2 γ 1), contain β 2 subunits associated with different α and γ subunits. Laminin 9 is restricted to the primary synaptic cleft and promotes the precise alignment of pre- and postsynaptic specializations. Laminin 11 lines the primary and secondary clefts, promotes presynaptic differentiation, and prevents Schwann cells from entering the synaptic cleft. The synaptic laminins provide a stop signal for axons at developing EPs and organize presynaptic differentiation.¹¹⁷ Mice with targeted deletions of *LAMB2* that encodes β 2-laminin show simplified presynaptic nerve endings with a decreased number of active zones, no clustering of the synaptic vesicles above the active zones, and extension of Schwann cell processes into the primary synaptic cleft.^{118,119} The MEPP frequency and quantal release by nerve impulse are reduced.¹²⁰

In addition to its presence at the EP, β 2-laminin is also highly expressed in renal glomeruli and the eye. *LAMB2* mutations in humans cause Pierson syndrome associated with ocular malformation (small nonreactive pupils, loss of accommodation, and abnormalities of the lens, cornea and retina) and a nephrotic syndromes fatal during infancy unless treated by a renal transplant (MIM 609049).

Recently Maselli and coworkers reported a 20-year-old woman with Pierson syndrome caused by two heteroallelic frameshifting mutations (1478delG and 4804delC) in *LAMB2* who also had a severe CMS.¹²¹ The nephrotic syndrome was corrected by a renal transplant at age 15 months. The patient had respiratory distress in infancy, delayed motor milestones, a decremental EMG response, limited ocular ductions, bilateral ptosis, severe proximal limb weakness, scoliosis, and required assisted ventilation at night and sometimes during the day. Notably, her condition was worsened by pyridostigmine but was improved by ephedrine. Morphologic and microelectrode studies of the anconeus muscle revealed findings similar to those found in mice with targeted deletion of *LAMB2*.

POSTSYNAPTIC CMS

The presently identified postsynaptic CMS arise from defects in AChR, rapsyn, the muscle specific tyrosine kinase (MuSK), Dok-7, plectin, and Na_v1.4, the voltage-gated sodium channel of adult muscle. Rapsyn under the influence of agrin, LRP4, Dok-7, and MuSK maintains a high concentration of AChR in the postsynaptic membrane by linking the AChR to the subsynaptic cytoskeleton. MuSK as well as Dok-7 are important for maturation and maintenance of the neuromuscular junction. Plectin is an intermediate filament linker protein concentrated at sites of mechanical stress. At the EP, it provides crucial structural support for the junctional folds.

CMS Caused By Mutations in AChR

Most postsynaptic CMS are caused by one or more mutations in an AChR subunit gene that decrease the expression or alter the kinetic properties of the receptor. The kinetic mutations fall into two distinct groups: (1) dominant, gain-of-function mutations that prolong the openings of the AChR channel and cause slow-channel syndromes, and (2) recessive loss-of function

mutations that shorten the openings of the AChR channel and cause fast-channel syndromes. Some low expressor mutations also have minor kinetic effects, and some kinetic mutations also reduce AChR expression. This chapter discusses the CMS caused by low-expressor mutations and the phenotypic consequences of the kinetic mutations. Chapter 10 describes the structural features of the AChR and analyzes the mechanistic consequences of the kinetic mutations.

Slow-Channel Syndromes

CLINICAL ASPECTS

The slow-channel syndrome (SCCMS) was recognized by Engel and coworkers in 1982.⁸ The distinguishing phenotypic features are dominant inheritance, selectively severe weakness of cervical, scapular, and finger extensor muscles, and variable weakness of other muscles. The affected muscles fatigue abnormally and are atrophic (Figs. 8-13). Except for the more severely affected patients, the cranial muscles are only mildly affected. The weakness and fatigability fluctuates but not as rapidly as in autoimmune MG. The tendon reflexes are usually normal but can be reduced in severely affected limbs. The severely affected muscles become atrophic. Progressive spinal deformities and respiratory embarrassment are common complications during the evolution of the illness. Some slow-channel CMS present in early life and cause severe disability by the end of the first decade;²⁶ others present later in life and progress gradually or in an intermittent manner, remaining quiescent for years or decades between periods of worsening.^{8,45,46}

ELECTROPHYSIOLOGY FEATURES

As in endplate AChE deficiency, single nerve stimuli evoke a repetitive CMAP that decrements abnormally on repetitive nerve stimulation but there is no loss of EP AChE. The consecutive spikes of the repetitive CMAP occur at 5- to 8-ms intervals, each smaller than the preceding one, and disappear after a brief voluntary contraction (Fig. 8-14A). The repetitive CMAP was present in all muscles, except for one patient who is a somatic and germ-line mosaic for the ϵ L269F mutation and has repetitive CMAPs only in proximal muscles. A decremental EMG response at 2 to 3 Hz stimulation is present in clinically affected muscles. The motor unit potentials fluctuate in shape and amplitude during voluntary activity.

In vitro microelectrode studies show the amplitude of the MEPP and MEPC significantly reduced in the more severely affected muscles. The quantal content of the EPP falls in the normal to low-normal range. Single-channel patch-clamp recordings demonstrate both normal and abnormally prolonged opening episodes of AChR. These reflect the activity of wild-type and mutant channels and account for the biexponential decay of the EP currents and potentials (Fig. 8-14B).^{45,46,50 26,49,122} Some mutant channels open even in the absence of ACh^{26,50} (Fig. 8-14C), as predicted by the allosteric scheme of receptor activation, causing a continuous cation leak into the postsynaptic region.

MORPHOLOGY

Light microscopic histochemical studies in the SCCMS show type 1 fiber preponderance, isolated or small groups of atrophic fibers of either histochemical type, tubular aggregates, and vacuoles in fiber regions near EPs.^{3,8} Other findings include abnormal variation in fiber size, fiber splitting, and sometimes mild to moderate increase of endomysial or perimysial connective tissue. AChE activity is present at all EPs. In the more severely affected muscles, the configuration of the EPs is often abnormal, with multiple small, discrete regions distributed over an extended length of the muscle fiber (Fig. 8-15A). In the most severe cases, focal calcium deposits can be demonstrated at the EPs with glyoxalbis-(*O*-hydroxyanyl) or alizarin-red dyes.⁸

On electron microscopy, the junctional folds of many EPs contain myriad pinocytotic